• MainImage1
  • MainImage2
  • MainImage3
1 2 3

Key Opinion Leaders

  • ChrisMcguigen1

Latest News

chicago: may 2014

Acelarin achieves high disease control rate in patients with advanced cancer. ProGem1 study results presented at the ASCO 50th Annual Meeting.

edinburgh: april 2014

NuCana announces a Series B financing of $57 million to fund expansion of clinical studies with its anti-cancer ProTides.

san diego: April 2014

NuCana presents exceptional data for anti-cancer agent, Acelarin, at the AACR Annual Meeting.